Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Rhenovia Files Two Patent Applications for RHEpatch™

Published: Friday, March 22, 2013
Last Updated: Friday, March 22, 2013
Bookmark and Share
An electronic transdermal patch for controlled drug delivery.

Rhenovia Pharma has announced that it has filed two patent applications for RHEpatch™, Rhenovia’s electronic transdermal patch for people suffering from chronic diseases.

RHEpatch was originally designed to optimize the delivery of drugs to patients suffering from diseases of the nervous system. However, Rhenovia now expects it to have a considerable impact across the entire health sector.

Its principal aim is to control dosing, treatment time and duration, day and night, for up to seven drugs administered to each patient. Control is achieved through a built-in electronic system pre-programmed by the doctor.

RHEpatch thus provides better control over the delivery of several drugs prescribed as a polytherapy, especially for the elderly.

RHEpatch is also designed to deliver the combinations of compounds needed to treat complex nervous system diseases such as Alzheimer’s disease.

It will also automatically control the administration of drugs, thus reducing the risk of patients forgetting. This facilitates treatment of patients with reduced mobility and prevents confused patients from taking repeated doses of drugs.

RHEpatch has many advantages over existing transdermal patches, which have drug release systems that are mainly passive (the treatment begins when the patch is put on and ends when it is taken off).

RHEpatch also indicates the amount of product actually delivered and the amount remaining in the patch.

In addition, unlike other transdermal patches, Rhenovia’s technology allows closely-controlled administration of several drugs through the same vector.

“This unique drug delivery device is going to have a major impact on the way medicines are used in the coming years,” said Dr. Serge Bischoff, president and CEO of Rhenovia. “It will enable doctors and nurses to manage treatment regimes more efficiently and more safely, as well as significantly improving patients’ quality of life.”

“RHEpatch is going to improve the treatment of diseases as complex as Parkinson’s, Alzheimer’s and Huntington’s, which require polytherapies for optimal efficacy,” said Professor Michel Baudry, vice-president and scientific director of Rhenovia.

“Delivering several drugs to the right place at the right time and in the right dose is a major challenge,” said Michel Faupel, vice-president of Rhenovia and the designer of RHEpatch.

Faupel continued, “Up to now, no one has succeeded in doing that satisfactorily. Yet this kind of approach is essential for ensuring effective long-term treatment of chronic diseases. By combining multitherapies derived from Rhenovia’s simulators with the controlled administration afforded by this intelligent patch, Rhenovia is convinced it can meet that challenge.”

Rhenovia’s industrial partner, Portmann Instruments AG, also contributed to the design of RHEpatch.

Portmann Instruments, which is based in Biel-Benken, Switzerland, is specialized in high-precision instrumentation and manufactures customized components for RHEpatch.

With the completion of a three-year EU Eurostars partnership program between Rhenovia and Portmann Instruments, RHEpatch has now reached the pre-industrialization prototype stage.

Following technological and biological proof-of-concept studies, Rhenovia is now looking for pharmaceutical, industrial and financial partners to move on to the industrialization and out-licensing stage.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
Hyperstable Peptides for 'On-Demand' Drugs
These small molecules can fold into different conformations that could allow for greater flexibility in precision drug design
Drug Leads Identified to Combat Heart Disease
Using three supercomputers, researchers surveyed protein structures through accelerated molecular dynamics.
Accelerating the Path to Molecules for Medicine
Researchers convert carbon-hydrogen bonds into nitriles - converting organic molecules into components of medicines.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos